Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
Globe Newswire (Thu, 19-Feb 8:39 AM ET)
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Globe Newswire (Wed, 18-Feb 8:20 AM ET)
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
Globe Newswire (Tue, 17-Feb 8:35 AM ET)
Moleculin Launches CEO Corner Platform to Share Strategic Insights
Globe Newswire (Fri, 13-Feb 8:32 AM ET)
ACCESS Newswire (Mon, 9-Feb 11:30 AM ET)
Globe Newswire (Thu, 5-Feb 9:15 AM ET)
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Globe Newswire (Tue, 13-Jan 8:55 AM ET)
Globe Newswire (Mon, 12-Jan 8:36 AM ET)
Globe Newswire (Wed, 17-Dec 8:31 AM ET)
Market Chameleon (Wed, 10-Dec 4:02 AM ET)
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Moleculin Biotech trades on the NASDAQ stock market under the symbol MBRX.
As of March 2, 2026, MBRX stock price declined to $2.38 with 79,285 million shares trading.
MBRX has a beta of 0.54, meaning it tends to be less sensitive to market movements. MBRX has a correlation of 0.00 to the broad based SPY ETF.
MBRX has a market cap of $4.93 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, MBRX traded as high as $618.75 and as low as $2.25.
The top ETF exchange traded funds that MBRX belongs to (by Net Assets): VXF.
MBRX has underperformed the market in the last year with a price return of -92.6% while the SPY ETF gained +16.7%. MBRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.1% and -45.2%, respectively, while the SPY returned +1.0% and +0.7%, respectively.
MBRX support price is $2.22 and resistance is $2.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBRX shares will trade within this expected range on the day.
